Lower levels of inflammatory markers and tumour burden is linked to improvements in PFS with Ide...

Prof Bertrand Arnulf speaks to ecacner about his study, KarMMa-3.
The trial analysis identified factors linked to longer progression-free survival (PFS) in multiple myeloma patients treated with idecabtagene vicleucel (ide-cel), a BCMA CAR T cell therapy.
Patients with longer PFS had lower baseline tumour burden and inflammatory markers.
Achieving and sustaining serum free light chain (sFLC) clearance post-infusion, along with higher and prolonged minimal residual disease (MRD) negativity, were strongly associated with longer PFS.
These findings emphasise the importance of managing baseline tumour burden and achieving early and sustained MRD negativity for optimal response to ide-cel therapy.